Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. B Smith

B Douglas Smith, M.D.

Professor of Oncology

Male

Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Professor of Oncology

Centers & Institutes

Departments

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-614-5068
Fax: 410-614-7437

Expertise

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Transplant, Bone Marrow Transplant, Chronic Myeloid Leukemia , Drug Development, Hematologic Malignancies, Leukemia, Medical Oncology, Myelodysplasia, Myelodysplastic Syndrome, Myeloproliferative Disorders

Research Interests

Acute and Chronic Leukemias; Myeloid Disorders and Bone Marrow Transplantation

    Additional Information

  • Education +

    Degrees

    • Drexel University College of Medicine / MD (1991)

    Residencies

    • Strong Memorial Hospital of the University of Rochester / Internal Medicine (1995)

    Fellowships

    • Johns Hopkins University School of Medicine / Medical Oncology (1998)
  • Research & Publications +

    Clinical Trial Keywords: Myeloid Disorders and Bone Marr, Acute and Chronic Leukemias

    Selected Publications

    Gore, S.D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C.B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J.E.; Rudek, M.A.; Zhao, M.; Smith, B.D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L.J.; Herman, J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006 Jun 15;66(12):6361-6369.

    Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.

    Huff, C.A.; Matsui, W.; Smith, B.D.; Jones, R.J. The paradox of response and survival in cancer therapeutics. Blood. 2006 Jan 15;107(2):431-434.

    Huff, C.A.; Matsui, W.H.; Douglas Smith, B.; Jones, R.J. Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer. 2006 Jun;42(9):1293-1297.

    Karp, J.E.; Smith, B.D. Exploiting oxidative damage to overcome resistance. Leuk Res. 2006 Oct;30(10):1213-1214.
    Karp, J.E.; Smith, B.D. Developmental clinical trials: building one step at a time. Leuk Res. 2006 Jul;30(7):765-766.

    Levis, M.; Brown, P.; Smith, B.D.; Stine, A.; Pham, R.; Stone, R.; Deangelo, D.; Galinsky, I.; Giles, F.; Estey, E.; Kantarjian, H.; Cohen, P.; Wang, Y.; Roesel, J.; Karp, J.E.; Small, D. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15;108(10):3477-3483.

    Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.

    Davis, A.P.; Sheppard, D.N.; Smith, B.D. Development of synthetic membrane transporters for anions. Chemical Society reviews. 2007 Feb;36(2):348-357.

    Karp, J.E.; Ricklis, R.M.; Balakrishnan, K.; Briel, J.; Greer, J.; Gore, S.D.; Smith, B.D.; McDevitt, M.A.; Carraway, H.; Levis, M.J.; Gandhi, V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15;110(6):1762-1769.

    Karp, J.E.; Smith, B.D.; Levis, M.J.; Gore, S.D.; Greer, J.; Hattenburg, C.; Briel, J.; Jones, R.J.; Wright, J.J.; Colevas, A.D. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-4473.

    Lin, T.L.; Vala, M.S.; Barber, J.P.; Karp, J.E.; Smith, B.D.; Matsui, W.; Jones, R.J. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007 Sep;21(9):1915-1920.

    Meng, X.W.; Lee, S.H.; Dai, H.; Loegering, D.; Yu, C.; Flatten, K.; Schneider, P.; Dai, N.T.; Kumar, S.K.; Smith, B.D.; Karp, J.E.; Adjei, A.A.; Kaufmann, S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem. 2007 Oct 12;282(41):29831-29846.

    Weir, E.G.; Ali Ansari-Lari, M.; Batista, D.A.; Griffin, C.A.; Fuller, S.; Smith, B.D.; Borowitz, M.J. Acute bilineal leukemia: a rare disease with poor outcome. Leukemia. 2007 Nov;21(11):2264-2270.

    Zhao, M.; Rudek, M.A.; He, P.; Hafner, F.T.; Radtke, M.; Wright, J.J.; Smith, B.D.; Messersmith, W.A.; Hidalgo, M.; Baker, S.D. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7.

    el-Shami, K.; Smith, B.D. Immunotherapy for myeloid leukemias: current status and future directions. Leukemia. 2008 Sep;22(9):1658-1664.

    Karp, J.E.; Smith, B.D.; Gojo, I.; Lancet, J.E.; Greer, J.; Klein, M.; Morris, L.; Levis, M.J.; Gore, S.D.; Wright, J.J.; Garrett-Mayer, E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15;14(10):3077-3082.

    Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008 Jan 1;68(1):190-197.

    Warlick, E.D.; O''Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.

    Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.

    Jinawath, N.; Norris-Kirby, A.; Smith, B.D.; Gocke, C.D.; Batista, D.A.; Griffin, C.A.; Murphy, K.M. A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice. J Mol Diagn. 2009 Jul;11(4):359-363.

    Karp, J.E.; Flatten, K.; Feldman, E.J.; Greer, J.M.; Loegering, D.A.; Ricklis, R.M.; Morris, L.E.; Ritchie, E.; Smith, B.D.; Ironside, V.; Talbott, T.; Roboz, G.; Le, S.B.; Meng, X.W.; Schneider, P.A.; Dai, N.T.; Adjei, A.A.; Gore, S.D.; Levis, M.J.; Wright, J.J.; Garrett-Mayer, E.; Kaufmann, S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14;113(20):4841-4852.

    Smith, B.D.; Karp, J.E. What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S296-301.

    Ye, Y.; McDevitt, M.A.; Guo, M.; Zhang, W.; Galm, O.; Gore, S.D.; Karp, J.E.; Maciejewski, J.P.; Kowalski, J.; Tsai, H.L.; Gondek, L.P.; Tsai, H.C.; Wang, X.; Hooker, C.; Smith, B.D.; Carraway, H.E.; Herman, J.G. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-8490.

    Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.

    Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.

    Griffiths, E.A.; Gore, S.D.; Hooker, C.; McDevitt, M.A.; Karp, J.E.; Smith, B.D.; Mohammad, H.P.; Ye, Y.; Herman, J.G.; Carraway, H.E. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma. 2010 Sep;51(9):1711-1719

    Griffiths, E.A.; Gore, S.D.; Hooker, C.M.; Mohammad, H.P.; McDevitt, M.A.; Smith, B.D.; Karp, J.E.; Herman, J.G.; Carraway, H.E. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010 Oct 3;5(7 ).

    Kanakry, C.G.; Hess, A.D.; Gocke, C.D.; Thoburn, C.; Kos, F.; Meyer, C.; Briel, J.; Luznik, L.; Smith, B.D.; Levitsky, H.; Karp, J.E. Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2010 Dec 16.

    Karp, J.E.; Blackford, A.; Smith, B.D.; Alino, K.; Seung, A.H.; Bolanos-Meade, J.; Greer, J.M.; Carraway, H.E.; Gore, S.D.; Jones, R.J.; Levis, M.J.; McDevitt, M.A.; Doyle, L.A.; Wright, J.J. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul;34(7):877-882.

    Li, L.; Zhao, M.; Navid, F.; Pratz, K.; Smith, B.D.; Rudek, M.A.; Baker, S.D. Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-3038.

    Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.

    Pratz, K.W.; Cho, E.; Levis, M.J.; Karp, J.E.; Gore, S.D.; McDevitt, M.; Stine, A.; Zhao, M.; Baker, S.D.; Carducci, M.A.; Wright, J.J.; Rudek, M.A.; Smith, B.D. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010 Aug;24(8):1437-1444.

    Smith, B.D.; Kasamon, Y.L.; Kowalski, J.; Gocke, C.; Murphy, K.; Miller, C.B.; Garrett-Mayer, E.; Tsai, H.L.; Qin, L.; Chia, C.; Biedrzycki, B.; Harding, T.C.; Tu, G.H.; Jones, R.; Hege, K.; Levitsky, H.I. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010 Jan 1;16(1):338-347.

    Smith, B.G.; Lewin, J.S. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2010 Jun;18(3):153-158.

    Stein, B.; Smith, B.D. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010 May;32(5):804-820.

    Karp, J.E.; Smith, B.D.; Resar, L.S.; Greer, J.M.; Blackford, A.; Zhao, M.; Moton-Nelson, D.; Alino, K.; Levis, M.J.; Gore, S.D.; Joseph, B.; Carraway, H.; McDevitt, M.A.; Bagain, L.; Mackey, K.; Briel, J.; Doyle, L.A.; Wright, J.J.; Rudek, M.A. Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Jan 14;Epub 1/18/11.

    Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
  • Academic Affiliations & Courses +
  • Activities & Honors +

    Memberships

    • American Associate for Advancement of Science
    • American Society of Clinical Oncology
    • American Society of Hematology
  • Videos & Media +
Is This You? Edit Profile
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.